




# 2nd annual prostate cancer forum

An Educational Initiative for Patients/Spouses, Advocates and Healthcare Professionals



# The Challenge: reduce incidence, death & suffering from prostate cancer

## Prostate Cancer Clinical States: A Framework for Clinical Practice, Drug Development, and Biomarker Qualification






## What is an National Cancer Institute (NCI)-designated cancer center?

-67 "designated" centers of excellence, dedicated to researching & improving: cancer prevention, diagnosis, and treatment

-"recognition of scientific excellence and outstanding leadership

-each composed of 4-10 programs of specific achievement

# TJU/ Kimmel Cancer Center Program dedicated entirely to improving prostate cancer detection & care



*Karen Knudsen, PhD  
(Leader)*

*Leonard Gomella, MD  
(Co-Leader)*

*Sandro Fatatis, MD PhD  
(Co-Leader)*

*Adam Dicker, MD PhD*

*Kevin Kelly, DO*

*Marja Nevalainen, MD PhD*

**\* 1 of only 8 designated programs of Prostate Cancer excellence by the National Cancer Institute**

## *Prostate Program: Specific Themes*




1. New detection methods
1. Improve hormone therapy
2. Novel treatment strategies for advanced disease
3. Precision medicine

# Prostate Cancer Program:


Cancer Biology



Pathology




Biochemistry



Radiology



Urology



Medical Oncology



Radiation Oncology




Dermatology



# Prostate Cancer Program:

- 1. New strategies for prevention, detection, & subtyping of early stage prostate malignancies
- 2. Define role of hormone action in prostate cancer development & progression
- 3. Novel treatment strategies
- 4. Predictive markers for rational therapy delivery (precision medicine)




Investigator	Organ confined disease	Locally advanced	Metastatic disease	Recurrent disease (CRPC)	Chemo-resistant disease
Comstock					
Den					
Fatatis					
Gomella					
Halpern					
Jiang					
Kelly					
Knudsen					
Languino					
Merry					
Morrione					
Nevalainen					
Pestell					
Rajsekaran					
Sawicki					
Trabulsi					
Wachsberger					
Wu					




# STRUCTURE: meeting goals

## Community Outreach



## Think Tank



## Training & Seminar Series



## Tumor Boards



Clinicians

Principal Investigators

Residents & Postdoctoral Fellows



PhD Students

Community




# Bench to Beside Translation

*Examples from 2011-12*




## Preclinical Finding

mTOR inhibitors induce upregulation of PI3K/AKT and Ras/Raf, SSTR may play a role



Phase II study: SOM230 LAR & Everolimus in CRPC

RB is a biomarker of therapeutic response in prostate cancer




Phase II study: Impact of RB status on combined abiraterone+cabazitaxel

PARP1 modulates AR signaling



Collaboration with U. Michigan: Phase II Hormone therapy + ABT-888

STAT5 is a critical effector of prostate cancer growth & metastasis



Trial targeting STAT5 in prostate cancer with AZD1480

## Multidisciplinary Care

### Enhancing Prostate Cancer Care Through the Multidisciplinary Clinic Approach: A 15-Year Experience


By Leonard G. Gomella, MD, Jianqing Lin, MD, Jean Hoffman-Censits, MD, Patricia Dugan, RN, Fran Guiles, RHIA, CTR, Costas D. Lallas, MD, Jaspreet Singh, DO, Peter McCue, MD, Timothy Showalter, MD, Richard K. Valicenti, MD, Adam Dicker, MD, and Edouard J. Trabulsi, MD

Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

### KCC GU Multi Disciplinary Clinic

- Weekly operation since 1996
- Urology, Rad Onc, Med Onc, Clinical Trials, Social Workers on site
- Path/case conference before
- We demonstrated for the first time that the multidisciplinary clinic approach to prostate cancer can significantly extend survival in men with high risk/locally advanced disease

Gomella, LG et al *Journal of Oncology Practice*, November 15, 2010



**Figure 1.** Kaplan-Meier survival of patients with newly diagnosed prostate cancer at the TJJU/KCC (1996-2008) and patients in NCI SEER (1997-2003). (A) Stage III (T3 N0 M0); (B) T4 N0 M0. TJJU, Thomas Jefferson University Hospital; KCC, Kimmel Cancer Center; NCI, National Cancer Institute; SEER, Surveillance, Epidemiology, and End Results.

*The Challenge:*  
*reduce incidence, death & suffering from prostate cancer*

*Our metric of success:*  
*elimination of disease*

